No one said the journal “does not matter”, they said that it is not relevant to regulatory approval. You took the conversation out of context.
Yes it helps to allow them to talk about the trial prior to approval, and it will allow for publicity. Lastly, it will also likely be helpful to their marketing efforts in the long-term.
But you too the post you responded to out of context. The key point was that it is not used during the regulatory approval process, and this is correct.
Market Data 
Markets 
AI
